On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.

Medicine marked a major milestone in April 2024, the U.S. Food and Drug Administration (FDA) said, when the agency announced it had approved its 50th biosimilar medication. Trastuzumab-strf, a biosimilar to the antineoplastic trastuzumab, had the honor of being the agency's 50th approval.

Merkel cell carcinoma (MCC) is a rare but aggressive form of skin cancer—although it is 40 times rarer than melanoma, it is 3–5 times more lethal. Approximately 3,000 new cases of Merkel cell carcinoma are diagnosed every year in the United States, but its incidence is increasing because of enhanced diagnostic techniques and the prevalence of risk factors.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto^®) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi^®) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).

The risk of dying from cancer has steadily declined in the United States over the past few decades, but Black individuals assigned female at birth still have some of the lowest survival rates. Although Black females are less likely to be diagnosed with cancer than White females, they are they more likely to die from it within five years, according to the National Cancer Institute. The disparity is particularly stark for breast cancer, which kills Black females at a 40% higher rate than White females, even though their rate of diagnosis is 4% lower.

On June 13, 2024, the U.S. Food and Drug Administration granted accelerated approval to repotrectinib (Augtyro^™) for adult and pediatric patients aged 12 and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.

Oncology nurses are frontrunners in identifying and managing symptoms experienced by people with cancer. From communication approaches and apps to integrative interventions, today’s tools can help nurses more efficiently assess and address side effects, thereby improving patient care.

On June 12, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo^®) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer that requires systemic therapy but is refractory to radioactive iodine (RAI), if RAI is appropriate.

Implementing a standard guideline for nursing management of patients receiving new U.S. Food and Drug Administration–approved chemotherapy, immunotherapy, and biotherapy decreased 1:1 patient–nursing hours by nearly 65% and saved more than $100,000 per year at one health system in south Florida, a team of nursing leaders reported in a poster presentation at the 49th annual ONS Congress^® in April 2024.